{"id":19740,"date":"2022-11-18T15:52:14","date_gmt":"2022-11-18T10:22:14","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=19740"},"modified":"2022-11-18T15:52:17","modified_gmt":"2022-11-18T10:22:17","slug":"gene-therapy-to-treat-complex-diseases","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases","title":{"rendered":"Gene Therapy: The Next Milestone in Treating Complex Diseases"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f825113c05c\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f825113c05c\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases\/#AAV_Vectors_in_Gene_Therapy\" >AAV Vectors in Gene Therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases\/#Gene_Therapy_Regulations\" >Gene Therapy Regulations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases\/#Gene_Therapy_Techniques\" >Gene Therapy Techniques<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases\/#Gene_Augmentation_Therapy\" >Gene Augmentation Therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases\/#Gene_Inhibition_Therapy\" >Gene Inhibition Therapy<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases\/#Gene_Therapy_Landscape_Across_Different_Therapeutic_Areas\" >Gene Therapy Landscape Across Different Therapeutic Areas<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases\/#Challenges_in_Gene_Therapy\" >Challenges in Gene Therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases\/#Whats_Cooking_in_the_Domain_of_Gene_Therapy_Development\" >What\u2019s Cooking in the Domain of Gene Therapy Development?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases\/#What_Lies_Ahead_in_Gene_Therapy_Market_Space\" >What Lies Ahead in Gene Therapy Market Space?<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Gene therapy is an experimental technique that introduces functional genes into a patient\u2019s body to counteract or replace defective ones, thereby curing disease without using pharmaceuticals, radiotherapy, or surgery. Genetic defects that are difficult to treat with drugs or antibodies can be treated with therapy with genes<\/p>\n\n\n\n<p>Depending on the type of cells treated, there are two <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/gene-therapies-whitepaper\">types of gene therapy<\/a>: Somatic gene therapy and Germline gene therapy<\/p>\n\n\n\n<p><strong>Somatic gene therapy:<\/strong> A section of DNA is transferred to any cell in the body that does not produce sperm or eggs. Gene therapy will not have any effect on the patient\u2019s children.<\/p>\n\n\n\n<p><strong>Germline gene therapy:<\/strong> A section of DNA is transferred to cells that produce eggs or sperm. Gene therapy&#8217;s effects will be passed down to the patient\u2019s children and future generations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-aav-vectors-in-gene-therapy\"><span class=\"ez-toc-section\" id=\"AAV_Vectors_in_Gene_Therapy\"><\/span><strong>AAV Vectors in Gene Therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The adeno-associated viral (AAV) vector is the safest and most effective vehicle among the several viral vectors used to deliver the genes of interest. Following a single injection of the vector, it can sustain long-term gene and protein expression.<\/p>\n\n\n\n<p>AAV vectors are the most widely used viral vectors for gene delivery to treat various human diseases. Recent advances in developing clinically desirable AAV capsids, optimizing genome designs, and harnessing revolutionary biotechnologies have all contributed significantly to the field\u2019s growth. Although the clinical success of <a href=\"https:\/\/www.delveinsight.com\/blog\/aav-vectors-in-gene-therapy-landscape\">rAAV gene therapy<\/a> is encouraging, the limitations and challenges of this gene delivery platform, such as concerns about rAAV manufacturing and immunological barriers to delivery, must also be acknowledged. These issues are being addressed by a growing field that includes multidisciplinary expertise.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gene_Therapy_Regulations\"><\/span><strong>Gene Therapy Regulations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Gene therapy products are biological products regulated by the FDA\u2019s Center for Biologics Evaluation and Investigation (CBER). Before beginning human clinical trials, an investigational new drug application (IND) must be submitted. Marketing a gene therapy product necessitates submission and approval of a biologics license application (BLA).<\/p>\n\n\n\n<p>Preclinical and clinical successes in AAV-mediated gene replacement, gene silencing, and gene editing have been reported. AAV has gained popularity as an ideal therapeutic vector, with a few <a href=\"https:\/\/www.delveinsight.com\/report-store\/adeno-associated-virus-vectors-in-gene-therapy-market\">AAV-based therapeutics<\/a> receiving regulatory approval in Europe and the United States. Nowadays, recombinant AAVs (rAAV) are used in gene therapy delivery in vivo. The groundbreaking research and outcomes of gene therapy led to the approval of <strong>Glybera<\/strong>, the first approved gene therapy by the European Medicines Agency (EMA), in 2012 to treat lipoprotein lipase deficiency.<\/p>\n\n\n\n<p>The FDA-approved gene therapy, <strong>Luxturna<\/strong>, received its regulatory approval after a few years. The approval of these gene therapies was a watershed moment for researchers working to develop successful gene therapy protocols for inherited human disorders.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gene_Therapy_Techniques\"><\/span><strong>Gene Therapy Techniques<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>There are several approaches to gene therapy. Among them are: Gene Augmentation Therapy and Gene Inhibition Therapy<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gene_Augmentation_Therapy\"><\/span><strong>Gene Augmentation Therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Gene augmentation therapy is used to treat diseases caused by a mutation in a gene that prevents it from producing a functional product, such as a protein. This is only successful if the disease\u2019s effects are reversible or have not caused permanent damage to the body. This can be used to treat loss-of-function disorders like cystic fibrosis, for example, by introducing a functional copy of the gene to correct the disease.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gene_Inhibition_Therapy\"><\/span><strong>Gene Inhibition Therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Gene inhibition therapy is suitable for the treatment of infectious diseases, cancer, and inherited diseases caused by abnormal gene activity. This therapy aims to inhibit the activity of a gene that promotes the growth of disease-related cells. For example, cancer is sometimes caused by the over-activation of an oncogene. So, by inhibiting the activity of that oncogene, it is possible to prevent further cell growth and stop cancer.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gene_Therapy_Landscape_Across_Different_Therapeutic_Areas\"><\/span><strong>Gene Therapy Landscape Across Different Therapeutic Areas<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Gene therapy is a promising treatment option for various diseases, and the general gene therapy strategy is simple. Gene therapy is the solution to many rare diseases and the light at the end of the tunnel for patients with complex genetic disorders. In addition, it is also used to treat cancer and viral infections. <a href=\"https:\/\/www.delveinsight.com\/report-store\/gene-therapy-in-oncology-innovation-to-commercialization-competitive-landscape\">Gene therapy for cancer<\/a> is on the verge of becoming a routine cancer treatment, potentially elevating this methodology to first-line therapy for neoplastic diseases.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17114218\/Gene-therapy-application.png\" alt=\"Gene therapy application\" class=\"wp-image-19756\" width=\"847\" height=\"250\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17114218\/Gene-therapy-application.png 847w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17114218\/Gene-therapy-application-300x89.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17114218\/Gene-therapy-application-150x44.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17114218\/Gene-therapy-application-768x227.png 768w\" sizes=\"(max-width: 847px) 100vw, 847px\" \/><figcaption><strong>Gene Therapy: Major Application and Various Products<\/strong><\/figcaption><\/figure>\n\n\n\n<p>Moreover, there are currently several technology platforms available for the discovery and development of various types of gene therapy. Indeed, advances in bioanalytical methods (such as genome sequencing) and genome editing and manipulation technologies (such as molecular switches) have enabled the creation of novel therapy development tools and platforms. Indeed, technology licensing is a lucrative source of income for industry stakeholders, particularly those with proprietary gene editing platforms. Given the growing demand for interventions that target the underlying (genetic) causes of diseases, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/gene-therapy-competitive-landscape\">gene therapy pipeline<\/a> is expected to continue to grow steadily.&nbsp;<\/p>\n\n\n\n<p>Over <strong>250+<\/strong> gene therapy companies are currently evaluating more than <strong>300<\/strong> gene therapies in various stages of development, and their anticipated acceptance in the gene therapy market would significantly increase market revenue.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Leading gene therapy companies such as <strong>Novartis, Johnson &amp; Johnson, Fibrocell Technologies, Pfizer, HELIXMITH Co., Ltd., Sarepta Therapeutics, Solid Biosciences Inc., Lexeo Therapeutics, Spark Therapeutics, Xalud Therapeutics, uniQure, Ultragenyx Pharmaceutical, Nanoscope Therapeutics, Homology Medicines, Freeline therapeutics, Amicus Therapeutics, REGENXBIO, Gyroscope Therapeutics, CSL, Sangamo Therapeutics, LYSOGENE, Asklepios BioPharmaceutical, Alcyone Therapeutics, Taysha Gene Therapies, Gensight Biologic, Vivet Therapeutics, BridgeBio, BioMarin Pharmaceutical, Neurophth Therapeutics, Abeona Therapeutics, Coave Therapeutics, Actus Therapeutics, Forge Biologics, Passage Bio, Aspa Therapeutics, Adrenas Therapeutics, ESTEVE, 4D Molecular Therapeutics, Bayer, LogicBio Therapeutics, Eli Lilly and Company, Adverum Biotechnologies, Libella Gene Therapeutics, Rocket Pharmaceuticals, Decibel therapeutics, DiNAQOR, Affinia Therapeutics, Lacerta Therapeutics, Atamyo Therapeutics, Apic Bio, Orchard Therapeutics, Nervosave Therapeutics, Maze Therapeutics, SOLA Biosciences, Benitec Biopharma, Hanugen Therapeutics, Exegenesis Bio, CANbridge Life Sciences Ltd, StrideBio, ENZERNA BIOSCIENCES INC., AAVogen, Capsigen, Code Biotherapeutics, Amarna Therapeutics, Poseida Therapeutics, Inc., bluebird bio, Genethon, Voyager Therapeutics, Jaguar Gene Therapy, LLC, Oxford Biomedica, Ocugen, Genprex, Beam Therapeutics, Neurogene Inc., Treeway, Oyster Point Pharma, Elicera Therapeutics AB, Generation Bio Co., Atsena Therapeutics, Precision Biosciences, Precigen, SELECTA BIOSCIENCES, Encoded Therapeutics, Graphite Bio, Nuevocor, M6P Therapeutics, SwanBio Therapeutics, AviadoBio, Myrtelle, Kriya Therapeutics, Inc., Senti Biosciences, Castle Creek Biosciences, Inc., Treadwell Therapeutics, Opus Genetics, Renovacor<\/strong>, and others are evaluating novel gene therapies candidate to improve the treatment landscape.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112558\/Key-Companies-Developing-Gene-Therapies.png\" alt=\"Gene therapy companies\" class=\"wp-image-19748\" width=\"589\" height=\"272\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112558\/Key-Companies-Developing-Gene-Therapies.png 589w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112558\/Key-Companies-Developing-Gene-Therapies-300x139.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112558\/Key-Companies-Developing-Gene-Therapies-150x69.png 150w\" sizes=\"(max-width: 589px) 100vw, 589px\" \/><figcaption><strong>Leading Players Working in the Gene Therapy Domain<\/strong><\/figcaption><\/figure>\n\n\n\n<p>The promising outcomes from ongoing gene therapy clinical trials initiatives will likely attract additional funding to support therapy product development initiatives in this domain. As a result, we believe that the <a href=\"https:\/\/www.delveinsight.com\/report-store\/gene-therapy-competitive-landscape\">global gene therapy market<\/a> will experience significant growth in the near future.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Challenges_in_Gene_Therapy\"><\/span><strong>Challenges in Gene Therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>AAV gene therapy requires improved bioavailability and cell selectivity. Another major issue with current gene transfer therapies is that the number of gene copies transferred to a cell is uncontrollable, resulting in unphysiological up or downregulation of the target gene, which can be neurotoxic in the long run.<\/p>\n\n\n\n<p>Furthermore, it is unknown which cell types are infected by AAV and which cell types benefit from gene transfer, especially since the endogenous version of the delivered gene is not normally expressed in these cells. Moreover, current gene transfer therapies employ aggressive constitutive promoters rather than tightly regulated endogenous promoters. To ensure long-term safety, future gene transfer therapies should allow for inducible regulation of the transferred gene in the event of relevant adverse effects.<\/p>\n\n\n\n<p>In addition, disorders in which several genes are involved in the underlying pathophysiology can present a significant challenge to developing gene therapy strategies. For example, several genes, including <strong>SOD1, C9ORF72, TARDBP, and FUS<\/strong>, have been linked to the onset of amyotrophic lateral sclerosis (ALS), though more than half of the cases are of unknown etiology.<\/p>\n\n\n\n<p>One way to address concerns about the current generation of gene therapy is to use a different delivery method. This is the approach taken by <strong>Generation Bio<\/strong>, which uses lipid nanoparticles &#8211; the same method used to deliver <a href=\"https:\/\/www.delveinsight.com\/report-store\/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market\">COVID mRNA vaccines<\/a>. Despite having no projects in the clinic, the group\u2019s vision initially gained traction, and the company conducted a <strong>USD 230 million <\/strong>IPO in 2020. However, things have not been going well since. In December, the company\u2019s stock plummeted after it revealed that promising mouse data from its hemophilia A project had not been translated to primates.<\/p>\n\n\n\n<p>So far, gene editing has mostly been used to treat rare diseases, but <strong>Verve Therapeutics<\/strong> hopes to change that. The group focuses solely on in vivo base editing <a href=\"https:\/\/www.delveinsight.com\/report-store\/gene-therapies-for-cardiomyopathies-market\">therapies for cardiovascular disease<\/a>. Given the inherent risk of gene editing, this may appear difficult to sell. However, Verve believes it can compete with currently <a href=\"https:\/\/www.delveinsight.com\/blog\/pcsk9-inhibitors-for-cholesterol-management\">marketed anti-PCSK9<\/a> approaches by improving compliance and, as a result, lowering the morbidity and mortality associated with very high cholesterol levels. The share price of the preclinical-stage group is well below its peak, but it is still worth around <strong>USD 1 billion<\/strong>, indicating that at least some investors are convinced.<\/p>\n\n\n\n<p>Their main challenges are limited delivery due to nonspecific binding, decreased in vivo stability, limited efficacy due to lysosomal degradation, and limited ability to access nuclear compartments for DNA cargo. Serum compounds can also disrupt their structure and promote aggregation, resulting in immunogenic responses and toxicity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Whats_Cooking_in_the_Domain_of_Gene_Therapy_Development\"><\/span><strong>What\u2019s Cooking in the Domain of Gene Therapy Development?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>On <strong>09 November 2022, Eikonoklastes Therapeutics<\/strong>, a preclinical biotech company developing first-in-class, AAV9-based gene therapy for treating sporadic and familial amyotrophic lateral sclerosis (ALS), announced that the ET-101 program had been granted Orphan Drug Designation (ODD) by the FDA.<\/li><li>On<strong> 08<\/strong> <strong>November 2022,<\/strong> <strong>BioMarin <\/strong>announced that the FDA had requested results from its ongoing Phase III GENEr8-1 study\u2019s upcoming 3-year data analysis. The additional information could be considered a significant change to the Biologics License Application that the company resubmitted in September. If this is the case, BioMarin representatives predict a three-month delay. An FDA advisory committee is expected to review the data ahead of the PDUFA deadline.<\/li><li>On<strong> 07<\/strong> <strong>November 2022,<\/strong> <strong>Cyagen<\/strong> announced a strategic partnership with Neurophth Therapeutics, Inc. to co-develop next-generation AAV gene therapy vectors for specific types of ophthalmic genetic disorders.<\/li><li>On<strong> 03<\/strong> <strong>November 2022,<\/strong> <strong>Santhera Pharmaceuticals and ReveraGen BioPharma\u2019s<\/strong> completed rolling submission of a New Drug Application (NDA) for the priority review of vamorolone in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-pipeline-insight\">treatment of Duchenne muscular dystrophy (DMD)<\/a> has been received by the FDA.<\/li><li>In <strong>October 2022, Astellas and Taysha Gene Therapies<\/strong> announced the strategic investment to support the development of Taysha\u2019s AAV-based gene therapy programs.<\/li><li>In <strong>October 2022, <\/strong>French companies formed a strategic alliance to cover cell and gene therapy (C&amp;GT) GMP manufacturing.<\/li><li>In <strong>October 2022, AVROBIO <\/strong>announced the patient dosing completion in the first <a href=\"https:\/\/www.delveinsight.com\/report-store\/cystinosis-market\">gene therapy clinical trial for cystinosis treatment<\/a>.<\/li><li>In <strong>October 2022, Xcell Biosciences Inc. (Xcellbio)<\/strong> and <strong>aCGT Vector<\/strong> announced a collaboration to improve manufacturing and analytic procedures used to develop personalized cell and gene therapies for cancer patients.<\/li><li>In <strong>August 2022,<\/strong> the FDA approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for treating adult and pediatric <a href=\"https:\/\/www.delveinsight.com\/report-store\/beta-thalassemia-market-forecast\">patients with beta-thalassemia<\/a> who require regular red blood cell transfusions.<\/li><li>In <strong>June 2022, Aruvant Sciences<\/strong> announced that Michael W. Kent, MD, pediatric blood and marrow transplant physician at Atrium Health\/Levine Children\u2019s Hospital, will be presenting new data on ARU-1801, one-time gene therapy for individuals with severe sickle cell disease (SCD), at the European Hematology Association (EHA) 2022 Hybrid Congress.&nbsp;<\/li><li>In <strong>March 2022, REGENXBIO<\/strong> announced that the FDA granted Rare Pediatric Disease Designation for RGX-202, which may entitle REGENXBIO to receive a priority review voucher which can be redeemed to obtain priority review for any subsequent marketing application and may be sold or transferred should a new BLA for RGX-202 be approved.<\/li><li>In <strong>January 2022, REGENXBIO Inc.<\/strong> announced the clearance of its Investigational New Drug application by the FDA to evaluate RGX-202, potential one-time <a href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-for-duchenne-muscular-dystrophy\">gene therapy for the treatment of Duchenne muscular dystrophy<\/a> in a first-in-human clinical trial. RGX-202 is designed to deliver a transgene for a novel microdystrophin that includes the functional elements of the C-Terminal (CT) domain found in naturally occurring dystrophin. RGX-202 uses REGENXBIO&#8217;s proprietary NAV\u00ae AAV8 vector.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Lies_Ahead_in_Gene_Therapy_Market_Space\"><\/span><strong>What Lies Ahead in Gene Therapy Market Space?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Gene therapies have revolutionized the last half-century from science fiction to the first commercialized products. New delivery strategies are constantly being developed or refined to achieve the most efficient and safest approach, allowing a single injection of gene therapy vector to provide a lifelong cure for severe IMDs. This novel therapy option will compete with other available therapies, either alone or in combination if necessary. Many unanswered questions remain, particularly regarding developing an adequate economic model to enable affordable <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/gene-therapies-whitepaper\">gene therapy products<\/a> for healthcare systems and the long-term efficacy and safety of these novel therapies.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112921\/Approved-gene-therapies.png\" alt=\"Approved gene therapies\" class=\"wp-image-19749\" width=\"1024\" height=\"768\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112921\/Approved-gene-therapies.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112921\/Approved-gene-therapies-300x225.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112921\/Approved-gene-therapies-150x113.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112921\/Approved-gene-therapies-768x576.png 768w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption><strong>Approved Gene Therapies Across Various Geographies<\/strong><\/figcaption><\/figure>\n\n\n\n<p>Currently, researchers are developing novel genotype-specific molecular therapies to become patient-specific and personalized gene therapy approaches to more efficiently correct the phenotype of genetic diseases. Furthermore, unlike previous viral delivery strategies, rAAV lacks viral genes, so there will be no active viral gene expression to amplify the immune response. Immune responses induced by AAV administration have been reported to compromise the outcomes of <a href=\"https:\/\/www.delveinsight.com\/blog\/aav-vectors-in-gene-therapy-landscape\">AAV-mediated gene therapy<\/a> in some experimental settings.<\/p>\n\n\n\n<p>Thus, several factors, including the route of administration, dose, serotype, host species, transgene and expression cassettes, and pre-existing immunity to AAV, may influence the occurrence of immune responses against AAV proteins. These studies and basic biology research have revealed many aspects of this vector that can be applied to future efforts.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/gene-therapy-competitive-landscape\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112513\/Gene-therapy-market-scenario-1024x256.png\" alt=\"Gene therapy market scenario\" class=\"wp-image-19747\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112513\/Gene-therapy-market-scenario-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112513\/Gene-therapy-market-scenario-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112513\/Gene-therapy-market-scenario-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112513\/Gene-therapy-market-scenario-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112513\/Gene-therapy-market-scenario-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112513\/Gene-therapy-market-scenario-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17112513\/Gene-therapy-market-scenario.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Gene therapy is an experimental technique that introduces functional genes into a patient\u2019s body to counteract or replace defective ones, thereby curing disease without using pharmaceuticals, radiotherapy, or surgery. Genetic defects that are difficult to treat with drugs or antibodies can be treated with therapy with genes Depending on the type of cells treated, there [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":19765,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[16988,19657,209,257,258,3153,259,260],"industry":[17225],"therapeutic_areas":[17242,17240,17238,17241,17228,17244,17234],"class_list":["post-19740","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-aav-gene-therapies","tag-aav-vectors-in-gene-therapy","tag-delveinsights-gene-therapy-reports","tag-gene-therapies","tag-gene-therapy","tag-gene-therapy-pipeline","tag-gene-therapy-pipeline-assessment","tag-gene-therapy-reports","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-genetic-disorders","therapeutic_areas-musculoskeletal","therapeutic_areas-oncology","therapeutic_areas-ophthalmology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gene Therapy: Next Generation Treatment Options for Complex Diseases<\/title>\n<meta name=\"description\" content=\"Over 250+ leading gene therapy companies are evaluating more than 300 gene therapies in various stages to treat different disorders\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gene Therapy: Next Generation Treatment Options for Complex Diseases\" \/>\n<meta property=\"og:description\" content=\"Over 250+ leading gene therapy companies are evaluating more than 300 gene therapies in various stages to treat different disorders\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-18T10:22:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-18T10:22:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17120415\/gene-therapy-for-complex-diseases.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gene Therapy: Next Generation Treatment Options for Complex Diseases","description":"Over 250+ leading gene therapy companies are evaluating more than 300 gene therapies in various stages to treat different disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases","og_locale":"en_US","og_type":"article","og_title":"Gene Therapy: Next Generation Treatment Options for Complex Diseases","og_description":"Over 250+ leading gene therapy companies are evaluating more than 300 gene therapies in various stages to treat different disorders","og_url":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-11-18T10:22:14+00:00","article_modified_time":"2022-11-18T10:22:17+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17120415\/gene-therapy-for-complex-diseases.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases","url":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases","name":"Gene Therapy: Next Generation Treatment Options for Complex Diseases","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17120415\/gene-therapy-for-complex-diseases.png","datePublished":"2022-11-18T10:22:14+00:00","dateModified":"2022-11-18T10:22:17+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Over 250+ leading gene therapy companies are evaluating more than 300 gene therapies in various stages to treat different disorders","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17120415\/gene-therapy-for-complex-diseases.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17120415\/gene-therapy-for-complex-diseases.png","width":772,"height":482,"caption":"gene-therapy-for-complex-diseases"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/11\/17120415\/gene-therapy-for-complex-diseases-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">AAV Gene therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">AAV vectors in gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight&#039;s Gene Therapy Reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gene Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gene therapy pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gene Therapy Pipeline Assessment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gene Therapy Reports<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AAV Gene therapies<\/span>","<span class=\"advgb-post-tax-term\">AAV vectors in gene therapy<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight&#039;s Gene Therapy Reports<\/span>","<span class=\"advgb-post-tax-term\">Gene Therapies<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy pipeline<\/span>","<span class=\"advgb-post-tax-term\">Gene Therapy Pipeline Assessment<\/span>","<span class=\"advgb-post-tax-term\">Gene Therapy Reports<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Nov 18, 2022","modified":"Updated on Nov 18, 2022"},"absolute_dates_time":{"created":"Posted on Nov 18, 2022 3:52 pm","modified":"Updated on Nov 18, 2022 3:52 pm"},"featured_img_caption":"gene-therapy-for-complex-diseases","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=19740"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19740\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/19765"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=19740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=19740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=19740"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=19740"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=19740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}